Tag Archive for: Viatris

Drugmaker Viatris said on Sunday it had reached agreements to divest some of its businesses for a total of up to $3.6 billion.

The companies on Wednesday secured the regulator’s approval for their eye drop Ryzvumi for the reversal of pharmacologically-induced mydriasis, as Viatris looks to add $1 billion in sales by 2028.

The U.S. health regulator has declined to approve a nasal spray that would have been the first needle-free emergency treatment for allergic reactions, a surprise decision that sent shares of its developer ARS Pharmaceuticals down 47% premarket.

The entry of biosimilars promotes healthy market competition. It can reduce the prices of branded biologic medicines, according to a new study from the University of Southern California’s Leonard D. Schaeffer Center for Health Policy & Economics.

The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc. of illegally monopolizing the market with its EpiPen auto-injector, a device used to treat severe allergic reactions.

Viatris Inc. announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7 as part of Viatris’ strategic update. Former Oyster Point Pharma CEO, Jeffrey Nau, Ph.D., MMS, will lead the new division.

Drugmaker Viatris Inc. is considering a potential sale of its consumer health assets in Europe in a deal that could be valued at over 3 billion euros ($2.9 billion), Bloomberg News reported on Tuesday, citing people familiar with the matter.

The U.S. Supreme Court on Monday declined to hear Biogen Inc’s (BIIB.O) bid to win reinstatement of a patent on the company’s blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc. subsidiary (VTRS.O) Mylan Pharmaceuticals Inc.

On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.

Biogen Inc. on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer’s disease drug being developed with Eisai Co. Ltd. and promising to draw lessons from the setbacks to its treatment Aduhelm.